Repaglinide

Product introduction:

Repaglinide is a type of diabetes drug. It is a non sulfonylurea type insulin releasing agent. It is mainly used to treat patients with type 2 diabetes mellitus (non-insulin-dependent) who have diet control, weight reduction and exercise can not effectively control hyperglycemia. In terms of chemical structure, repaglinide is a carbamoyl methyl benzoic acid derivative, which is a fast acting and short-time insulin secreting postprandial blood glucose regulator. Its mechanism is mainly through closing β Potassium channels on the cell membrane cause calcium ion influx and increase the concentration of calcium ion in cells, thus stimulating insulin secretion. However, it is different from the receptor site of sulfonylurea drugs, and the drugs do not enter β Cells do not inhibit protein synthesis or directly cause insulin exocytosis.

CAS：135062-02-1

Structural type:

Molecular formula:C₂₇H₃₆N₂O₄

Molecular weight: 452.59

Purpose: non sulfonylurea oral hypoglycemic agents are used to treat type II diabetes. Used as a hypoglycemic drug.